NewAmsterdam Pharma Co N.V. (NAMS) stock forecast and price target
Price $20.14 · data as of November 13, 2026
12-month price target
Average target$50.11
Upside / downside+148.8%
Analysts15
ConsensusStrong buy
Low $37.56Average $50.11High $60.29
Gold marker: average target · white marker: today’s price ($20.14)
Analyst ratings
Strong buy 3Buy 12Hold 1Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-1.33 | +8.8% | $35M |
| Next fiscal year ends December 31, 2027 | $-1.90 | −39.1% | $43M |
| Next quarter ends December 31, 2026 | $-0.41 | +24.0% | $12M |
| Quarter after ends March 31, 2027 | $-0.49 | −43.5% | $1M |
Consensus of the analysts covering NewAmsterdam Pharma Co, updated daily. In the last 30 days 3 estimates were raised and 1 lowered.
Frequently asked questions
What is the NewAmsterdam Pharma Co stock price target?
The average 12-month target from 15 analysts is $50.11, 148.8% above the current price of $20.14 Targets range from $37.56 to $60.29.
Is NewAmsterdam Pharma Co a buy according to analysts?
The consensus rating is “Strong buy” (3 strong buy, 12 buy, 1 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is NewAmsterdam Pharma Co expected to earn?
Analysts expect EPS of $-1.33 for the fiscal year ending December 31, 2026 and $-1.90 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.